Immunology

mRNA-based vaccines against SARS-CoV-2 do not stimulate interferon stimulatory gene expression in individuals affected by Aicardi Goutières Syndrome

1. Asako Takanohashi
2. Mohamad-Gabriel Alameh
3. Sarah Woidill
4. Julia Hacker
5. Benjamin Davis
6. Guy Helman
7. Francesco Gavazzi
8. Laura Adang
9. Russell D’Aiello
10. Patrick Winters
11. Devon Cordova
12. Taibeen Khandaker
13. Houping Ni
14. Ying Tam
15. Paulo Lin
16. Drew Weissman
17. Justine Shults
18. Adeline Vanderver

Reviewed by ScreenIT

Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2

1. Meng Yuan
2. Yiquan Wang
3. Huibin Lv
4. Timothy J.C. Tan
5. Ian A. Wilson
6. Nicholas C. Wu

Reviewed by ScreenIT

Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis

1. Zaigham Abbas Rizvi
2. Prabhakar Babele
3. Srikanth Sadhu
4. Upasna Madan
5. Manas Ranjan Tripathy
6. Sandeep Goswami
7. Shailendra Mani
8. Sachin Kumar
9. Amit Awasthi
10. Madhu Dikshit

Reviewed by Rapid Reviews Infectious Diseases, ScreenIT

The ATLAS™ screening assay reveals distinct CD4 ⁺ and CD8 ⁺ SARS-CoV-2 antigen response profiles which have implications to Omicron cellular immunity

1. James J. Foti
2. Kevin Lema
3. Justin Strickland
4. Emily Tjon
5. Adrienne Li
6. Amalia Rivera
7. Crystal Cabral
8. Laura Cormier
9. Louisa Dowal
10. Sudhir Rao
11. Vijetha Vemulapalli
12. Jessica B. Flechtner

Reviewed by ScreenIT

SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression

1. Najla Arshad
2. Maudry Laurent-Rolle
3. Wesam S. Ahmed
4. Jack Chun-Chieh Hsu
5. Susan M. Mitchell
6. Joanna Pawlak
7. Debrup Sengupta
8. Kabir H. Biswas
9. Peter Cresswell

Reviewed by ScreenIT

Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation

1. Nazar Beirag
2. Chandan Kumar
3. Taruna Madan
4. Mohamed H. Shamji
5. Roberta Bulla
6. Daniel Mitchell
7. Valarmathy Murugaiah
8. Martin Mayora Neto
9. Nigel Temperton
10. Susan Idicula-Thomas
11. Praveen M. Varghese
12. Uday Kishore

Reviewed by ScreenIT

Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters

1. Geraldine Nouailles
2. Julia M. Adler
3. Peter Pennitz
4. Stefan Peidli
5. Luiz Gustavo Teixeira Alves
6. Morris Baumgardt
7. Judith Bushe
8. Anne Voss
9. Alina Langenhagen
10. Christine Langner
11. Ricardo Martin Vidal
12. Fabian Pott
13. Julia Kazmierski
14. Aileen Ebenig
15. Mona V. Lange
16. Michael D. Mühlebach
17. Cengiz Goekeri
18. Szandor Simmons
19. Na Xing
20. Azza Abdelgawad
21. Susanne Herwig
22. Günter Cichon
23. Daniela Niemeyer
24. Christian Drosten
25. Christine Goffinet
26. Markus Landthaler
27. Nils Blüthgen
28. Haibo Wu
29. Martin Witzenrath
30. Achim D. Gruber
31. Samantha D. Praktiknjo
32. Nikolaus Osterrieder
33. Emanuel Wyler
34. Dusan Kunec
35. Jakob Trimpert

Reviewed by Rapid Reviews Infectious Diseases, ScreenIT

Single-cell glycomics analysis by CyTOF-Lec reveals glycan features defining cells differentially susceptible to HIV

1. Tongcui Ma
2. Matthew McGregor
3. Leila Giron
4. Guorui Xie
5. Ashley F George
6. Mohamed Abdel-Mohsen
7. Nadia R Roan

• Curated by eLife

  Evaluation Summary:

  This study applies a new novel method of single cell detection to biologically relevant systems to try to understand whether glycans on the surface of CD4+T cells impact HIV susceptibility. They find that cells expressing higher levels of fucose and sialic acid are more likely to be infected with to HIV than those with low levels. The findings point to glycans as a biomarker and potential determinant for HIV cells susceptibility and open the door to new avenues for studies the interplay between cell surface glycans and viral infections.

  (This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. Reviewer #1 agreed to share their name with the authors.)

Reviewed by eLife

Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors

1. Matheswaran Kandasamy
2. Uzi Gileadi
3. Pramila Rijal
4. Tiong Kit Tan
5. Lian N Lee
6. Jili Chen
7. Gennaro Prota
8. Paul Klenerman
9. Alain Townsend
10. Vincenzo Cerundolo

• Curated by eLife

  Evaluation Summary:

  This paper describes an approach in which a non-replicating influenza virus expressing a cancer testis antigen is used to induce a systemic and mucosal antigen specific T cell responses. The authors find that this immune response is sufficient to reduce tumor burden following intravenous or subcutaneous tumor challenge. This paper is potentially interesting to tumor-immunity researchers.

  (This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. The reviewers remained anonymous to the authors.)

Reviewed by eLife

Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody

1. Sanjeev Kumar
2. Anamika Patel
3. Lilin Lai
4. Chennareddy Chakravarthy
5. Rajesh Valanparambil
6. Elluri Seetharami Reddy
7. Kamalvishnu Gottimukkala
8. Meredith E. Davis-Gardner
9. Venkata Viswanadh Edara
10. Susanne Linderman
11. Kaustuv Nayak
12. Kritika Dixit
13. Pragati Sharma
14. Prashant Bajpai
15. Vanshika Singh
16. Filipp Frank
17. Narayanaiah Cheedarla
18. Hans P. Verkerke
19. Andrew S. Neish
20. John D. Roback
21. Grace Mantus
22. Pawan Kumar Goel
23. Manju Rahi
24. Carl W. Davis
25. Jens Wrammert
26. Sucheta Godbole
27. Amy R. Henry
28. Daniel C. Douek
29. Mehul S. Suthar
30. Rafi Ahmed
31. Eric Ortlund
32. Amit Sharma
33. Kaja Murali-Krishna
34. Anmol Chandele

Reviewed by ScreenIT